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Research
It is a sobering thought that we are scarcely any 
more advanced in our concepts than were Jackson 
and his contemporaries. Our knowledge is more 
detailed, diagnosis of cerebral lesions is more 
reliable, the techniques of neurosurgery are 
immeasurably improved, but we still know very 
little about how to treat Idiopathic Epilepsy. The 
difficulty lies in the nature of the disease, fits 
occur at unpredictable intervals. All attempts to 
produce a reliable test for epilepsy have failed, and 
hence all measurements of the effects of drugs 
must be based on statistical techniques. The use of 
laboratory animals in whom epileptogenic are 
induced can provide material but computer 
techniques must be used to make the very large 
numbers of measurements needed to obtain 
statistically significant results.
The Patient
With all the statistics, the computers, and the 
drama of Neurosurgery we must not forget the 
individual for whom all this work is being carried 
out. The patient, as I said at the start, suffers not 
from Fite but from Fear. His own fear that he may 
suffer a convulsion at a dangerous or socially
embarrassing moment. The fears of his parents and 
his friends, of his employer and of society at large. 
It is an open question whether the truculence of 
the "epileptic personality" is a result of any 
specific organic leison or merely a response to the 
intolerable pressures of "living with fits". 
Education can help Society to loose its irrational 
fears. Psychiatrists and Social Workers can offer 
support. The Doctor's role is to try and find and 
treat the cause, but most important of all, to help 
the patient to plan his life with realism and to live 
it with confidence.
References
1. Berger H. 1929. Uber das Elektren- 
kephalogramm des Menschen. Arch. Psychiat 
87:527-570. Ibid. 1931, 94:16-61; 1933, 
100:301-320; 1933, 101:452-469; 1934, 
102:538-557; 1936, 104:678-689.
2. Selected Writings of John Hughlings Jackson. 
Basic Books, Inc. N.Y. 1958. Ed. James Taylor.
3. Epilepsy and the Functional Anatomy of the 
Human Brain by W. Penfield & H. Jasper. 
Churchill, 1954.
CURRENT TOPICS IN EPILEPSY
IAN TULLOCH
Introduction
Human epilepsies, by definition, are recurrent, 
self-sustained, paroxysmal disorders of brain 
function characterised by excessive firing of 
cerebral neurones. The underlying biochemical and 
morphological disturbances in the brain which are 
responsible for epilepsy are not clearly understood 
except that they appear to be diverse and hence 
the immediate difficulty in advancing a common 
mechanism for these disorders. Most probably 
they are different diseases but the clinical 
manifestations of these are similar. This view 
would certainly be compatible with the complex 
nature of neuronal control mechanisms both at the 
cellular and organisational level. In this article 
there will be a stress on possible biochemical 
disorders both in humans and in experimental 
epilepsies, the drug treatment of these, and an 
evaluation of the clinical relevance of experimental 
animal models.
Many cases of epilepsy are idiopathic, in that 
no underlying lesion can be found in the brain. 
This has led to the view that everybody has a 
threshold for epilepsy and it is this which 
determines whether or not seizures may develop. 
Genetic make-up seems to be important in some 
cases, especially gene-dependent errors of 
metabolism which are inherited as autosomal 
recessives, such as phenylketonuria, which results 
in accumulation of products of phenylalanine, and 
this is often accompanied by convulsions but the 
cause-effect mechanism is unknown. Numerically, 
however, these particular diseases are rare. Conrad 
(1935—38) did a study of twins with idiopathic 
and symptomatic epilepsy. He studied mono­
zygotic and dizygotic twins and his results showed 
that 19 out of 22 of the monozygotic twin pairs 
were concordant with regard to epilepsy, and in 
127 dizygotic pairs there was concordance only in 
approximately 4%. His studies were an attempt at 
measuring the correlations between a given genetic 
make-up, and brain electrical activity as measured 
by the EEG; he concluded that heredity did have a 
determining role in epilepsy which was idiopathic 
in nature. Symptomatic epilepsy, i.e. where there 
is a known lesion, was also included and heredity 
only played a minor part in this syndrome.
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Refsum (1972) proposed a hypothesis of a 
polygenic influence being important in a 
predisposition to epilepsy and this interplays with 
various environmental precipitating factors.
Classes of epilepsy
Epilepsy can be divided into two main groups:
(a) Focal epilepsy
In many areas of the brain localised lesions 
can cause focal epilepsy. Usually the hyper­
active neurones are localised in or around the 
lesion area. Lesions can be caused at birth, 
after head, injury or more obviously by a 
tumour. These lesioned areas exhibit 
abnormal firing as shown by the EEG, The 
temporal lobe is particular susceptible to 
lesions and much interest has been shown in 
this type of epilepsy.
(b) Generalised Epilepsies
Petit mal and grand mal come under this 
heading and are characterised by abnormal 
electrical activity in large areas of brain 
rather than in a focal area. These are the 
more serious types of epilepsy since they 
result in loss of consciousness and severe 
seizures may occur. Petit mal is a very 
characteristic type of epilepsy in which there 
is a sudden complete loss of consciousness 
lasting for a few seconds followed by a 
sudden and complete return to normality. 
Grand mal is only diagnosed when un­
consciousness and convulsions are known to 
have occurred. An important point here is 
that focal epilepsy can progress to a grand 
mal seizure, but grand mal seizures 
frequently occur independently of focal 
epilepsy.
These epilepsies are the main ones, but there 
are many others which have different clinical 
manifestations.
Neurochemistry of Epilepsy
(a) Problems
Biochemical research into epilepsy is greatly 
restricted by the difficulty in obtaining 
human biopsy and autopsy material. A  
study of a particular lesioned area from the 
brain may not reveal much concerning the 
initial cause of the epilepsy since the tissue 
that is actually epileptic may only be a small 
part of the sample or the tissue may be 
gliosed and neurones may be degenerated. 
Pope has proposed that the actual epileptic 
area is on the periphery of the lesion and
perhaps more emphasis should be placed on 
studies of this region.
This difficulty in obtaining neural tissue and 
the need for screening tests for anti-epileptic 
drugs has necessitated the use of exper­
imental animal models. These models should 
ideally show similar behavioural and 
electrical manifestations to the particular 
type of human epilepsy under investigation. 
Many experimental models are now in use 
for different types of epilepsy, and this 
allows for a detailed biochemical and 
histological analysis of the brain. A  detailed 
description of all models is not presented 
but only the most useful ones.
(a) Animal Models
(1) Focal epilepsy
Included in these are the topical convulsant 
metals, e.g. cobalt and alumina cream. These 
agents can be used to produce localised 
lesions in the brain but degeneration can be 
quite widespread as has been shown by 
histological study of the cobalt metal. 
Cellular destruction occurs at the lesion site 
and makes biochemical analysis of the tissue 
difficult and so many studies have investi­
gated the secondary focus. Briefly, this is a 
focus which is homotopic to the original 
focus, if cortical in position, and has the 
advantage that it is an epileptic focus not 
accompanied by gross cellular destruction.
Drugs are tested for their ability to 
prevent focal discharge or to prevent seizure 
propagation and part of the clinical 
relevance of the model can be evaluated 
from these studies. Increasingly, more 
workers are doing biochemical studies on 
experimental models and trying to relate 
these to the human situation. For example, 
the recent work of van Gelder showed that 
in freshly excised cortical tissue from focal 
epileptogenic lesions in man there was a fall 
in glutamic acid, GABA, taurine and a 
significant rise in glycine in the area of the 
active focus. These amino acids are thought 
to have a transmitter function in the CNS 
and a change in their levels may indicate an 
imbalance between excitatory and inhibitory 
mechanisms. In a parallel study by Koyama 
on cobalt focal epileptogenic lesions in the 
cat, significant and very similar changes in 
transmitter levels were observed in the 
actively discharging focus.
An advantage of an animal model is 
that the development of epilepsy can be 
studied and Koyama was able to show that 
the fall in glutamic acid as measured in the
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tissue was paralleled with an increased 
release of free glutamic acid from the 
cortical surface and the fall in GABA was a 
later development. Perhaps the initial release 
of glutamic acid, a postulated excitatory 
CNS transmitter, might be responsible for 
the development of a pool of hyperactive 
neurones. The fall in GABA, probably an 
inhibitor transmitter, is probably a result of 
a decrease in its precursor glutamic acid but 
it may be an important biochemical change 
with regard to the chronic nature of the 
experimental model.
Cation levels, intracellular and 
extracellular, are very important for neurone 
stability. The enzyme Na-K ATPase is 
membrane bound and requires ATP to 
transport Na+ and K+ ions across the 
neuronal membrane. Another important 
function of this enzyme is the re-uptake of 
transmitteres into nerve endings, a 
mechanism which is very important in the 
inactivation of transmitter activity on the 
post-synaptic receptor. Impairment of 
activity in this enzyme system might result 
in changes in ionic gradients and in 
alterations in transmitter release and 
re-uptake.
Hunt and Craig in a recent study on 
the cobalt model in rats, investigate cation 
levels and Na+-K ATPase activity in brain 
during the development of epilepsy. Their 
results were indicative of a change in ion 
transport since they reported an increase in 
Ca+, Na+, Mg-++- and a fall in K+ Na-K 
ATPase and protein content in the area of 
the lesion. No significant changes were 
detected in the secondary focus of 
epileptogenic activity.
(2) Generalised Epilepsies
I. Grand Mal
Two models are most commonly used in the 
evaluation of drugs effective in grand mal:
(i) The Maximal Electroshock Seizure
(MES) pattern test.
This is a relatively crude test that involves 
measurement of the dose of a drug that 
abolishes the tonic extensor component of 
the seizure induced by supra-maximal 
stimulation of the brain in 50% of all 
animals. Basically it is a measure of the 
drug's ability to prevent propagation of the 
epileptic discharge through brain tissue, and 
it is valuable since all drugs that have 
anti-grand mal activity in man are effective 
in the MES test in animals. Drugs that are
effective in cases of grand mal were 
discovered by empirical screening in various 
animal models, particularly the MES 
technique and the literature is lacking in 
detailed information on the mechanisms of 
drug action.
(ii) A  possible action of anti-grand mal 
drugs is an inhibition of post-tetanic 
potentiation. Briefly, this is an enhancement 
of release of transmitter/volley for periods 
lasting up to several minutes after 
stimulating a nerve cell at a high frequency. 
A  model frequently used is:
Recording the Mono-synaptic reflex in the 
spinal cord. After tetanic stimulation at the 
dorsal root for a minute has ceased, the 
amplitude of the mono-synaptic reflex 
increases. This increase can be almost 
completely blocked by diphenylhydantoin, a 
drug which is used extensively in chronic 
treatment of grand mal.
II. Petit Mal
The models for petit mal are not so well 
developed or tested as the grand mal models 
but a few models are useful. Systemic 
administration of pentylenetetrazol induces 
seizures which are decreased by anti-petit 
mal drugs such as ethosuximide. This model 
is poorly understood, especially since there 
are conflicting reports on what the action of 
pentylenetetrazole is.
These and many other experimental models 
have been used to study transmitters and energy 
metabolism in the CNS and a good, deal of 
information is available relating to possible causal 
mechanisms for epilepsy. Manipulation of central 
transmitter levels by various methods has 
implicated all the known central transmitters in 
experimental epilepsy, but at the clinical trial 
level, as well as in experimental models, 
disappointing results have been obtained by 
attempts to treat epilepsy by altering specific 
transmitter levels in a known manner. This is 
perhaps forwarding a  rather bleak picture 
concerning the rational treatment of epilepsy, but 
a certain degree of success has been obtained.
A  notable example is the amino acid, GABA, 
for which there is good evidence from release, 
uptake, localisation and iontophoretic studies that 
it js an inhibitory transmitter in the CNS and at 
the neuromuscular junction in the crayfish. 
Glutamic acid is the precursor of GABA and the 
enzyme responsible for the catalysis is glutamate 
decarboxylase which requires vitamin B6 as a 
co-factor. An important point is that the co-factor 
is weakly bound and, therefore, the enzyme is very 
susceptible to a vitamin B6 deficiency or B6
anti-metabolites. B6 deficiency is not responsible 
for many cases of epilepsy but at least this 
evidence links a specific transmitter with a known 
cause of epilepsy, i.e. vitamin B6 deficiency. This 
disease is probably due to some genetic 
abnormality.
Recent work on taurine, a possible neuro- 
transmitter has shown that this amino acid 
prevents epilepsy in cobalt induced epilepsy in the 
cat and mouse, and van Gelder found a decrease in 
taurine levels in human focal epilepsy in the region 
of the focus. Physiological data indicate that 
iontophoretically applied taurine depresses activity 
in Renshaw cells, spinal interneurones and cerebral 
cortex cells which is strongly indicative of an 
inhibitory neurotransmitter function. Taurine is 
being used in clinical trials but no results are 
available as yet.
Changes in glutamate and GABA could 
possibly be due to a fault in the brain energy 
metabolism. The GABA shunt pathway provides 
an alternative route to part of the TCA cycle 
which is the chief energy generating system in 
oxidative metabolism. If some form of metabolic 
uncoupling is possible between the TCA cycle and 
the GABA shunt this could result in a change of 
GABA and glutamate levels. Alternatively the TCA 
cycle may not be properly functioning in cells and 
this could have the effect as previously mentioned 
as well as causing an ATP deficiency which may in 
itself be responsible for epilepsy. Certainly many 
experiments using metabolic poisons, e.g. cyanide, 
ouabain, have shown that convulsions are 
produced by these agents but the exact mechanism 
responsible for epileptic discharge of a cell is 
debatable.
An essential requirement for proper brain cell 
function is the maintenance of ionic gradients 
across neuronal and glial membranes and hence 
correct polarisation, e.g. high Na+ concentration 
extracellularly and low intracellularly in the 
normal state. The stress is on ion distribution 
rather than absolute amounts and research into 
this is limited because of the difficulty in the 
measurement of these gradients. Research into 
transmitter involvement in epilepsy is also 
complicated by compartmentation of these into 
metabolic and functional, i.e. neurotransmitter 
pools.
Clinical Aspects
Although changes in neurotransmitters, energy 
metabolism and ions have been implicated in 
experimental and human epilepsy, it is quite 
disappointing that so few new forms of successful
treatment have emerged. Although newer drugs are 
available, some of the drugs of choice are virtually 
unchanging and perhaps the major reason for this 
is that the new drugs are no real improvement on 
existing, well-tried drugs. Attention has recently 
centred on the correct plasma concentrations of 
anti-epileptic drugs and Marselli et al. have drawn 
attention to the lack of correlation between oral 
dose of diphenylhydantoin and plasma con­
centration in human patients. The main reasons 
for this are the differences between individuals in 
the rate of metabolism of drugs.
Adverse side effects are a major feature of the 
use of anti-epileptics since they are not specifically 
acting on epileptic cells but on normal cells as 
well. This is probably a major determining factor 
in the use of a given drug. A  study by Gibberd 
throws light on the importance of clinical 
supervision over patients in their abilities to follow 
given dosage instructions. The reason for this may 
be that the side effects of the drugs are less 
tolerable than the actual epilepsy and this is 
clearly evidence for improvement in drug therapy. 
Correct plasma concentrations of anti-epileptic 
drugs are very important for them to be effective 
and also to reduce the side-effects.
Newer drugs are emerging for the treatment of 
some forms of epilepsy. The drug Diazepam, 
which is a benzodiazepine tranquilliser, has been 
found to be very effective in the treatment of 
status epilepticus in both adults and children and 
carbamazepine which is closely related to 
imipramine chemically, is effective in grand mal 
and temporal lobe epilepsy.
Concluding Remarks
Diphenylhydantoin and phenobarbitone are 
given on a chronic basis to epileptics and studies 
using animal models have rarely investigated 
chronic drug effects. Empiric screening of drugs in 
a battery of animal models has the disadvantage 
that it does not necessarily single out drugs that 
could be effective on a chronic basis. Onset of 
human epilepsy, especially after head injury, can 
occur and it would be very helpful if this could be 
prevented, possibly by administration of an anti­
epileptic drug immediately after the injury. 80%  of 
epileptics are treated by drugs and many of these 
are helped a great deal. However, there is a need to 
specify the modes of action of the anti-epileptic 
drugs and to develop drugs which are more specific 
to the disease.
7
In order to find out at first hand about this 
disabling condition. Res Medica went to see Mr 
James Glover, who for several years has been 
suffering from petit mal epilepsy- He told us about 
his condition:
"M y  first inclination on taking these turns 
came wth sick tremors in my stomach. They then 
developed into the tremor followed by a black-out 
lasting a few minutes; This can happen anywhere, 
any time. It is like losing my memory. If I am 
talking I completely change the subject I am 
discussing. When the turn is over I return to where 
I was with the original conversation.
This started after a fall from a 20ft scaffold. I 
was sent to hospital and had an E.E.G. for the top 
half of my brain: no damage was found. This was 
twelve- years ago. They associated it with my 
having tubercular meningitis when I was 19 years 
old. I was put on varipus drugs over the years 
without much success. Last year my doctor and I 
agreed that I should try the Andrew Duncan Clinic 
in Edinburgh to see if the illness was psy­
chological. When I was having my last talk with 
the doctor I took one of these turns. The doctor 
made arrangements for me to have a lower E.E.G. 
done. This determined that my brain is damaged 
and an operation could cure me.
My experience with petit mal is one of 
frustration and annoyance. It has affected my 
working life. I am an electrical engineer and when 
I first took these turns was working with the 
transmission section of S.S.E.B. My work involved 
heights and high voltage electricity, also driving. I
was retired from S.S.E.B. on the grounds that I 
was a risk.
I am now in charge of maintenance at the 
Roxburghe Hotel, Edinburgh, and have worked 
there for three years handling all types of electrical 
and mechanical maintenance. My work is regarded 
as very satisfactory.
My home and social life is normal except for 
my complete impotence on which I blame these 
turns.
I am chairman of two committees for 
handicapped children: one is a parents' committee, 
the other is a rebuilding fund for the first 
secondary school for these children. I have proved 
that the latter will work and is worthwhile for the 
children's education and confidence.
M y own little girl is slightly retarded and when 
I discovered this I blamed myself for her 
condition. When I found out that my wife was 
pregnant again I wanted the birth terminated. 
However, the doctor advised against it, and I thank 
God as everything has turned out fine.
The effects of this illness cause great 
embarrassment when in company as I not only do 
rather stupid things but sometimes can lose 
control of my bladder, and having to explain the 
situation to strangers is rather awkward.
I have now been assured by my neurologist 
that an operation is definitely possible and may be 
carried out in the very near future. This will be a 
very happy day for me as it should mean a return 
to normal life and I can now set my sights higher 
as these turns have held me back enormously 
regarding promotion."
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